Clinical Trials
Clinical trials are research studies that test medicines in development to see if they are safe and effective. We can only advance therapies with the partnership of many different people, including patients who volunteer to participate in these studies.
Enrolling
This is a randomized, controlled, multicenter, open-label Phase 3 clinical trial to study the investigational oncolytic immunotherapy RP1 given in combination with nivolumab versus Physician’s Choice treatment for patients with advanced melanoma.
ARTACUS
This is a Phase 1B/2 clinical trial to study the effects of the investigational oncolytic immunotherapy RP1 for the treatment of cutaneous malignancies in patients who underwent either a kidney, liver, heart, lung, or other solid organ transplant, or hematopoietic cell transplantation. Researchers will study the safety of this treatment in patients and also evaluate its ability to shrink tumors.
This is a randomized, controlled, multicenter, open-label Phase 2/3 clinical trial to study the investigational oncolytic immunotherapy RP2 given in combination with nivolumab versus Ipilimumab in Combination with Nivolumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.
This is a Phase II study that will evaluate whether treatment with RP2 can provide additional efficacy as 1L treatment combined with Atezolizumab plus Bevacizumab in patients with locally advanced unresectable or metastatic HCC or provide efficacy as 2L treatment combined with atezolizumab plus bevacizumab in patients with recurrent or metastatic HCC.
This is a Phase 1/2 clinical trial to study the investigational oncolytic immunotherapy RP1 given in combination with nivolumab. Researchers will study the safety of this treatment in these patients and also evaluate its ability to shrink tumors.
This is a Phase 1 clinical trial to study the investigational oncolytic immunotherapy RP2 given both alone and in combination with nivolumab to patients with solid tumors. Researchers will study the safety of this treatment in these patients and also evaluate its ability to shrink tumors.
Active, not recruiting
CERPASS
This is a randomized Phase 2 clinical trial to compare the effects of cemiplimab alone versus a combination of cemiplimab and the investigational oncolytic immunotherapy RP1. Researchers will study the effectiveness of these treatments against tumors and how long the effect lasts for.